Af­ter a PhI­II fail­ure, the FDA de­liv­ers Blue­print an ex­pect­ed CRL

Some CRLs come as lit­tle sur­prise.

This morn­ing, the FDA re­ject­ed Blue­print Med­i­cines’ ap­pli­ca­tion to have their can­cer drug Ay­vak­it (avapri­tinib) ap­proved for fourth-line gas­troin­testi­nal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.